10-Q 1 kopn-20180929x10xq.htm 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 29, 2018

¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission file number 0-19882

KOPIN CORPORATION
(Exact name of registrant as specified in its charter)

Delaware |  | 04-2833935
State or other jurisdiction of incorporation or organization |  | (I.R.S. Employer Identification No.)
125 North Drive, Westborough, MA |  | 01581-3335
(Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (508) 870-5959

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer |  | ¨ |  |  | Accelerated filer |  | x
Non-accelerated filer |  | ¨ |  |  | Smaller reporting company |  | ¨
|  |  |  |  | Emerging growth company |  | ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ¨ No x
1

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class | Outstanding as of November 5, 2018 |
Common Stock, par value $0.01 | 73,135,253 |

2

Table of Contents
Kopin Corporation
INDEX

|  | Page No.
Part I – Financial Information |
Item 1. | Condensed Consolidated Financial Statements (Unaudited) | 3
| Condensed Consolidated Balance Sheets at September 29, 2018 (Unaudited) and December 30, 2017 | 4
| Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 29, 2018 and September 30, 2017 | 5
| Condensed Consolidated Statements of Comprehensive Loss (Unaudited) for the three and nine months ended September 29, 2018 and September 30, 2017 | 6
| Condensed Consolidated Statements of Stockholders' Equity (Unaudited) for the nine months ended September 29, 2018 and September 30, 2017 | 7
| Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 29, 2018 and September 30, 2017 | 8
| Notes to Unaudited Condensed Consolidated Financial Statements | 9
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 24
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 29
Item 4. | Controls and Procedures | 30
Part II – Other Information | 30
Item 1. | Legal Proceedings | 30
Item 1A. | Risk Factors | 31
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 31
Item 6. | Exhibits | 32
Signatures |  | 33

3

Table of Contents
Part 1. FINANCIAL INFORMATION

Item 1. | Condensed Consolidated Financial Statements (Unaudited)

3

Table of Contents
KOPIN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

| September 29, 2018 |  | December 30, 2017
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 19,367,048 |  |  | $ | 24,848,227 |
Marketable debt securities, at fair value | 26,835,968 |  |  | 43,907,457 |
Accounts receivable, net of allowance of $468,000 in 2018 and $149,000 in 2017 | 2,628,139 |  |  | 3,955,123 |
Contract assets and unbilled receivables | 1,935,262 |  |  | 704,863 |
Inventory | 4,953,908 |  |  | 5,080,797 |
Prepaid taxes | 133,445 |  |  | 264,352 |
Prepaid expenses and other current assets | 1,044,374 |  |  | 978,677 |
Total current assets | 56,898,144 |  |  | 79,739,496 |
Property, plant and equipment, net | 5,075,602 |  |  | 5,077,043 |
Goodwill | 1,761,136 |  |  | 1,780,247 |
Intangible assets, net | 220,909 |  |  | 883,636 |
Other assets | 2,096,578 |  |  | 3,842,068 |
Equity investments | 5,572,816 |  |  | — |
Total assets | $ | 71,625,185 |  |  | $ | 91,322,490 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 4,229,387 |  |  | $ | 4,918,605 |
Accrued payroll and expenses | 2,169,492 |  |  | 1,636,512 |
Accrued warranty | 587,000 |  |  | 649,000 |
Contract liabilities and billings in excess of revenue earned | 428,642 |  |  | 896,479 |
Other accrued liabilities | 2,095,098 |  |  | 2,066,025 |
Income tax payable | 1,573 |  |  | 1,416,892 |
Deferred tax liabilities | 547,266 |  |  | 520,000 |
Total current liabilities | 10,058,458 |  |  | 12,103,513 |
Deferred revenue, net of current portion | 154,769 |  |  | 374,171 |
Asset retirement obligations | 260,660 |  |  | 269,877 |
Other long-term obligations | 1,925,911 |  |  | 1,195,082 |
Stockholders’ equity: |  |  |
Preferred stock, par value $.01 per share: authorized, 3,000 shares; none issued | — |  |  | — |
Common stock, par value $.01 per share: authorized, 120,000,000 shares; issued 81,124,758 shares in 2018 and 80,201,313 shares in 2017; outstanding 73,135,253 shares in 2018 and 73,058,783 shares in 2017 | 776,485 |  |  | 775,720 |
Additional paid-in capital | 334,985,791 |  |  | 331,119,340 |
Treasury stock (4,513,256 shares in 2018 and 2017, at cost) | (17,238,669 | ) |  | (17,238,669 | )
Accumulated other comprehensive income | 3,036,681 |  |  | 3,564,779 |
Accumulated deficit | (261,631,136 | ) |  | (240,121,901 | )
Total Kopin Corporation stockholders’ equity | 59,929,152 |  |  | 78,099,269 |
Noncontrolling interest | (703,765 | ) |  | (719,422 | )
Total stockholders’ equity | 59,225,387 |  |  | 77,379,847 |
Total liabilities and stockholders’ equity | $ | 71,625,185 |  |  | $ | 91,322,490 |

See notes to unaudited condensed consolidated financial statements
4

Table of Contents
KOPIN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

| Three Months Ended |  | Nine Months Ended
| September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Revenues: |  |  |  |  |  |  |
Net product revenues | $ | 3,643,619 |  |  | $ | 5,589,402 |  |  | $ | 13,160,507 |  |  | $ | 14,501,945 |
Research and development revenues | 1,482,711 |  |  | 549,765 |  |  | 3,563,341 |  |  | 1,942,819 |
| 5,126,330 |  |  | 6,139,167 |  |  | 16,723,848 |  |  | 16,444,764 |
Expenses: |  |  |  |  |  |  |
Cost of product revenues | 3,659,800 |  |  | 4,144,884 |  |  | 11,219,741 |  |  | 11,379,467 |
Research and development | 4,599,266 |  |  | 5,253,860 |  |  | 13,577,075 |  |  | 14,213,950 |
Selling, general and administration | 7,166,137 |  |  | 5,344,999 |  |  | 21,011,050 |  |  | 16,186,946 |
| 15,425,203 |  |  | 14,743,743 |  |  | 45,807,866 |  |  | 41,780,363 |
Loss from operations | (10,298,873 | ) |  | (8,604,576 | ) |  | (29,084,018 | ) |  | (25,335,599 | )
Other income: |  |  |  |  |  |  |
Interest income | 160,875 |  |  | 191,613 |  |  | 486,239 |  |  | 611,532 |
Other income | 241,466 |  |  | (109,546 | ) |  | 1,360,822 |  |  | 215,883 |
Foreign currency transaction (losses) gains | (227,447 | ) |  | 224,370 |  |  | (254,615 | ) |  | (410,373 | )
Gain on investments | — |  |  | — |  |  | 2,849,816 |  |  | 274,000 |
| 174,894 |  |  | 306,437 |  |  | 4,442,262 |  |  | 691,042 |
Loss before benefit (provision) for income taxes and net loss (income) attributable to noncontrolling interest | (10,123,979 | ) |  | (8,298,139 | ) |  | (24,641,756 | ) |  | (24,644,557 | )
Tax benefit (provision) | 316,000 |  |  | (4,500 | ) |  | 115,000 |  |  | 1,141,500 |
Net loss | (9,807,979 | ) |  | (8,302,639 | ) |  | (24,526,756 | ) |  | (23,503,057 | )
Net loss (income) attributable to noncontrolling interest | 16,596 |  |  | 55,217 |  |  | (41,862 | ) |  | 65,223 |
Net loss attributable to Kopin Corporation | $ | (9,791,383 | ) |  | $ | (8,247,422 | ) |  | $ | (24,568,618 | ) |  | $ | (23,437,834 | )
Net loss per share |  |  |  |  |  |  |
Basic and diluted | $ | (0.13 | ) |  | $ | (0.11 | ) |  | $ | (0.34 | ) |  | $ | (0.34 | )
Weighted average number of common shares outstanding |  |  |  |  |  |  |
Basic and diluted | 73,135,253 |  |  | 72,187,688 |  |  | 73,102,979 |  |  | 69,117,640 |

See notes to unaudited condensed consolidated financial statements
5

Table of Contents
KOPIN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)

|  | Three Months Ended |  | Nine Months Ended
|  | September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Net loss | $ | (9,807,979 | ) |  | $ | (8,302,639 | ) |  | $ | (24,526,756 | ) |  | $ | (23,503,057 | )
Other comprehensive (loss) income, net of tax: |  |  |  |  |  |  |
| Foreign currency translation adjustments | 68,890 |  |  | (272,618 | ) |  | (266,807 | ) |  | 658,443 |
| Unrealized holding (losses) gains on marketable securities | (103,212 | ) |  | (29,584 | ) |  | (313,348 | ) |  | 108,196 |
| Reclassification of holding losses (gains) in net loss | 27,620 |  |  | (1,238 | ) |  | 25,852 |  |  | (5,138 | )
Other comprehensive (loss) income, net of tax | (6,702 | ) |  | (303,440 | ) |  | (554,303 | ) |  | 761,501 |
Comprehensive loss | $ | (9,814,681 | ) |  | $ | (8,606,079 | ) |  | $ | (25,081,059 | ) |  | $ | (22,741,556 | )
Comprehensive loss (income) attributable to the noncontrolling interest | 13,788 |  |  | 63,306 |  |  | (15,657 | ) |  | 79,660 |
Comprehensive loss attributable to controlling interest | $ | (9,800,893 | ) |  | $ | (8,542,773 | ) |  | $ | (25,096,716 | ) |  | $ | (22,661,896 | )

See notes to unaudited condensed consolidated financial statements
6

Table of Contents
KOPIN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)

| Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Income |  | Accumulated Deficit |  | Total Kopin Corporation Stockholders’ Equity |  | Noncontrolling Interest |  | Total Stockholders’ Equity
| Shares |  | Amount |  |  |  |  |  |  |
Balance, December 30, 2017 | 77,572,038 |  |  | $ | 775,720 |  |  | $ | 331,119,340 |  |  | $ | (17,238,669 | ) |  | $ | 3,564,779 |  |  | $ | (240,121,901 | ) |  | $ | 78,099,269 |  |  | $ | (719,422 | ) |  | $ | 77,379,847 |
Stock-based compensation | — |  |  | — |  |  | 3,878,619 |  |  | — |  |  | — |  |  | — |  |  | 3,878,619 |  |  | — |  |  | 3,878,619 |
Vesting of restricted stock | 80,000 |  |  | 800 |  |  | (800 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Repurchases of restricted stock to satisfy tax withholding obligations | (3,530 | ) |  | (35 | ) |  | (11,368 | ) |  |  |  |  |  |  |  | (11,403 | ) |  | — |  |  | (11,403 | )
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (528,098 | ) |  | — |  |  | (528,098 | ) |  | (26,205 | ) |  | (554,303 | )
Adoption of accounting standards (Note 2) | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,059,383 |  |  | 3,059,383 |  |  | — |  |  | 3,059,383 |
Net (loss) income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (24,568,618 | ) |  | (24,568,618 | ) |  | 41,862 |  |  | (24,526,756 | )
Balance, September 29, 2018 | 77,648,508 |  |  | $ | 776,485 |  |  | $ | 334,985,791 |  |  | $ | (17,238,669 | ) |  | $ | 3,036,681 |  |  | $ | (261,631,136 | ) |  | $ | 59,929,152 |  |  | $ | (703,765 | ) |  | $ | 59,225,387 |

| Common Stock |  | Additional Paid-in Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Income |  | Accumulated Deficit |  | Total Kopin Corporation Stockholders’ Equity |  | Noncontrolling Interest |  | Total Stockholders’ Equity
| Shares |  | Amount |  |  |  |  |  |  |
Balance, December 31, 2016 | 76,640,943 |  |  | $ | 766,409 |  |  | $ | 328,524,644 |  |  | $ | (42,741,551 | ) |  | $ | 1,570,971 |  |  | $ | (214,042,787 | ) |  | $ | 74,077,686 |  |  | $ | 141,957 |  |  | $ | 74,219,643 |
Stock-based compensation | — |  |  | — |  |  | 2,484,757 |  |  | — |  |  | — |  |  | — |  |  | 2,484,757 |  |  | — |  |  | 2,484,757 |
Vesting of restricted stock | 60,000 |  |  | 600 |  |  | (600 | ) |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Other comprehensive income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | 775,938 |  |  | — |  |  | 775,938 |  |  | (14,437 | ) |  | 761,501 |
Sale of unregistered stock | — |  |  | — |  |  | — |  |  | 25,502,882 |  |  | — |  |  | (838,632 | ) |  | 24,664,250 |  |  | — |  |  | 24,664,250 |
Net loss | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (23,437,834 | ) |  | (23,437,834 | ) |  | (65,223 | ) |  | (23,503,057 | )
Balance, September 30, 2017 | 76,700,943 |  |  | $ | 767,009 |  |  | $ | 331,008,801 |  |  | $ | (17,238,669 | ) |  | $ | 2,346,909 |  |  | $ | (238,319,253 | ) |  | $ | 78,564,797 |  |  | $ | 62,297 |  |  | $ | 78,627,094 |

See notes to unaudited condensed consolidated financial statements
7

Table of Contents
KOPIN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

| Nine Months Ended
| September 29, 2018 |  | September 30, 2017
Cash flows used in operating activities: |  |  |
Net loss | $ | (24,526,756 | ) |  | $ | (23,503,057 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
Depreciation and amortization | 1,688,715 |  |  | 1,878,363 |
Stock-based compensation | 3,878,619 |  |  | 2,990,157 |
Foreign currency losses | 269,239 |  |  | 400,542 |
Change in allowance for bad debt | (333,889 | ) |  | — |
Unrealized gain on investments | (2,849,816 | ) |  | (274,000 | )
Deferred income taxes | 70,803 |  |  | (1,170,017 | )
Other non-cash items | 519,027 |  |  | 781,927 |
Changes in assets and liabilities, net of acquired assets and liabilities: |  |  |
Accounts receivable | 1,504,218 |  |  | 71,400 |
Contract assets | 1,619,875 |  |  | — |
Inventory | (1,551,859 | ) |  | (2,519,197 | )
Prepaid expenses and other current assets | 144,421 |  |  | 13,345 |
Accounts payable and accrued expenses | (664,524 | ) |  | 1,743,215 |
Billings in excess of revenue earned | 49,174 |  |  | (253,480 | )
Net cash used in operating activities | (20,182,753 | ) |  | (19,840,802 | )
Cash flows provided by investing activities: |  |  |
Other assets | (7,616 | ) |  | (79,916 | )
Capital expenditures | (959,488 | ) |  | (1,341,744 | )
Proceeds from sale of marketable debt securities | 21,858,785 |  |  | 33,395,422 |
Purchase of marketable debt securities | (4,910,630 | ) |  | (22,974,668 | )
Cash paid for equity investment | (1,000,000 | ) |  | — |
Cash paid for acquisition, net of cash acquired | — |  |  | (3,690,047 | )
Net cash provided by investing activities | 14,981,051 |  |  | 5,309,047 |
Cash flows (used in) provided by financing activities: |  |  |
Sale of unregistered stock | — |  |  | 24,664,250 |
Settlements of restricted stock for tax withholding obligations | (11,403 | ) |  | — |
Net cash (used in) provided by financing activities | (11,403 | ) |  | 24,664,250 |
Effect of exchange rate changes on cash | (268,074 | ) |  | (72,436 | )
Net (decrease) increase in cash and cash equivalents | (5,481,179 | ) |  | 10,060,059 |
Cash and cash equivalents: |  |  |
Beginning of period | 24,848,227 |  |  | 15,822,495 |
End of period | $ | 19,367,048 |  |  | $ | 25,882,554 |
Supplemental disclosure of cash flow information: |  |  |
Income taxes paid | $ | 1,300,000 |  |  | $ | — |

See notes to unaudited condensed consolidated financial statements
8

Table of Contents
KOPIN CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. | BASIS OF PRESENTATION

The condensed consolidated financial statements of Kopin Corporation as of September 29, 2018 and for the three and nine month periods ended September 29, 2018 and September 30, 2017 are unaudited and include all adjustments that in the opinion of management, are necessary to present fairly the results of operations for the periods then ended. These condensed consolidated financial statements should be read in conjunction with the Company’s financial statements and notes thereto, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2017. The results of the Company's operations for any interim period are not necessarily indicative of the results of the Company's operations for any other interim period or for a full fiscal year. The Company reclassified certain prior period amounts to conform to the current period presentation. As used in this report, the terms "we", "us", "our", "Kopin" and the "Company" mean Kopin Corporation and its subsidiaries, unless the context indicates another meaning.

2. | ACCOUNTING STANDARDS

Recently Issued Accounting Pronouncements
Leases
In February 2016, the FASB issued ASU No. 2016-02 (Topic 842) Leases, which requires lessees to recognize a right-of-use asset and lease liability for most lease arrangements. The Company will adopt the standard effective at the beginning of fiscal year 2019. Interpretations are on-going and could have a material impact on the Company's implementation. Currently, the Company expects that the adoption of the ASU 2016-02 (Topic 842) Leases will have a material impact on its consolidated balance sheet due to the recognition of right-of-use assets and lease liabilities principally for certain leases currently accounted for as operating leases, but the Company does not expect it to have a material impact on our results of operations or liquidity.
Recently Adopted Accounting Pronouncements
Recognition and Measurement of Financial Assets and Liabilities
The Company adopted ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities and the related amendments on December 31, 2017 (the first day of the Company's fiscal year 2018). This standard amends various aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The Company adopted the measurement alternative for equity investments without readily determinable fair values (often referred to as cost method investments) on a prospective basis. As a result, these investments will be revalued upon occurrence of an observable price change for similar investments and for impairments.
Revenue from Contracts with Customers
The Company adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) effective December 31, 2017 and applied the modified retrospective method. The Company recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company expects the impact of the adoption of the new standard to be material to the Company's results of operations on an ongoing basis.
Significant Accounting Policies Update
The Company's significant accounting policies are detailed in "Note 1: Summary of Significant Accounting Policies" of our Annual Report on Form 10-K for the fiscal year ended December 30, 2017. Significant changes to the Company's accounting policies as a result of adopting Topic 606 are discussed below.
Revenue Recognition
Substantially all of our revenues are either derived from the sales of components for use in military applications or our wearable technology components that can be integrated to create industrial and consumer headset systems. We also have development contracts for the design, manufacture and modification of products for the U.S. government or a prime contractor for the U.S. government (“U.S. government”) or for a customer that sells into the industrial or consumer markets. The Company's contracts with the U.S. government are typically subject to the Federal Acquisition Regulations (“FAR”) and are priced based on estimated or actual costs of producing goods. The FAR provides guidance on the types of costs that are allowable in establishing prices for goods provided under U.S. government contracts. The pricing for non-U.S. government contracts is based on the specific negotiations with each customer.
9

Table of Contents
Our fixed-price contracts with the U.S. government may result in revenue recognized in excess of amounts actually billed. We disclose the in excess of revenues over amounts actually billed as Contract assets and unbilled receivables on the balance sheet. Amounts billed and due from our customers are classified as Accounts receivable on the balance sheets. In some instances, the U.S. government retains a small portion of the contract price until completion of the contract. The portion of the payments retained until final contract settlement is not considered a significant financing component because the intent is to protect the customer. For contracts with the U.S. government, we typically receive interim payments either as work progresses, we achieve certain milestones or based on a schedule in the contract. We recognize a liability for these advance payments in excess of revenue recognized and present it as Contract liabilities and billings in excess of revenue earned on the balance sheets. The advanced payment typically is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. For industrial and consumer purchase orders, we typically receive payments within 30 to 60 days of shipments of the product, although for some purchase orders, we may require an advanced payment prior to shipment of the product.
To determine the proper revenue recognition method for complex contracts with the same customer, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation. This evaluation requires significant judgment and the decision to combine a group of contracts or separate the combined or single contract into multiple performance obligations could change the amount of revenue and profit recorded in a given period. For most of our development contracts and contracts with the U.S government, the customer contracts with us to provide a significant service of integrating a set of components into a single unit. Hence, the entire contract is accounted for as one performance obligation. Less common, however, we may promise to provide distinct goods or services within a contract in which case we separate the contract into more than one performance obligation. If a contract is separated into more than one performance obligation, we allocate the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. In cases where we sell standard products, the observable standalone sales are used to determine the standalone selling price.
The Company recognizes revenue from a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For certain contracts that meet the foregoing requirements, primarily international direct commercial and military sale contracts, we recognize revenue once we have obtained all regulatory approvals.
Commencing in 2018 for certain contracts with the U.S. government, the Company recognizes revenue over time as we perform because of continuous transfer of control to the customer and the lack of an alternative use for the product. The continuous transfer of control to the customer is supported by liability clauses in the contract that allow the U.S. government to unilaterally terminate the contract for convenience, pay us for costs incurred plus a reasonable profit and take control of any work in process. For contracts with commercial customers, while the contract may have a similar liability clause, our products historically have an alternative use and thus, revenue is recognized at a point in time.
In situations where control transfers over time, revenue is recognized based on the extent of progress towards completion of the performance obligation. We generally use the cost-to-cost approach to measure the extent of progress towards completion of the performance obligation for our contracts because we believe it best depicts the transfer of assets to the customer, which occurs as we incur costs on our contracts. Under the cost-to-cost measure approach, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. Revenues are recorded proportionally as costs are incurred.
Accounting for design, development and production contracts requires judgment relative to assessing risks, estimating contract revenues and costs, and making assumptions for schedule and technical issues. Due to the size and nature of the work required to be performed on many of our contracts, the estimation of total revenue and cost at completion is complicated and subject to many variables. Contract costs include material, labor and subcontracting costs, as well as an allocation of indirect costs. We have to make assumptions regarding the number of labor hours required to complete a task, the complexity of the work to be performed, the availability and cost of materials, and performance by our subcontractors. For contract change orders, claims or similar items, we apply judgment in estimating the amounts and assessing the potential for realization. These amounts are only included in contract value when they can be reliably estimated and realization is considered probable. If our estimate of total contract costs or our determination of whether the customer agrees that a milestone is achieved is incorrect, our revenue could be overstated or understated and the profits or loss reported could be wrong.
For our commercial customers, the Company's revenue is recognized when obligations under the terms of a contract with our customer is satisfied; generally this occurs with the transfer of control of the Company's products or services. Revenue is recorded as the amount of consideration we expect to receive in exchange for transferring goods or providing services.
10

Table of Contents
Provisions for product returns and allowances are recorded in the same period as the related revenues. We analyze historical returns, current economic trends and changes in customer demand and acceptance of product when evaluating the adequacy of sales returns and other allowances. Certain product sales are made to distributors under agreements allowing for a limited right of return on unsold products. Sales to distributors are primarily made for sales to the distributors' customers and not for stocking of inventory. We delay revenue recognition for our estimate of distributor claims of right of return on unsold products based upon our historical experience with our products and specific analysis of amounts subject to return based upon discussions with our distributors or their customers. Sales, value add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue.
The rights and benefits to the Company's intellectual property are conveyed to certain customers through technology license agreements. These agreements may include other performance obligations including the sale of product to the customer. When the license is distinct from other obligations in the agreement, the Company treats the license and other performance obligations as separate performance obligations. Accordingly, the license is recognized at a point in time or over time based on the standalone selling price. The sale of materials is recognized at a point in time, which occurs with the transfer of control of the Company's products or services. In certain instances, the Company is entitled to sales-based royalties under license agreements. These sales-based royalties are recognized when they are earned.
The cumulative effect of the changes made to the Company's consolidated December 31, 2017 balance sheet for the adoption of ASU 2014-09, Revenue from Contracts with Customers (Topic 606) was as follows:

Balance Sheet | Balance at December 30, 2017 |  | Adjustments due to Topic 606 |  | Balance at December 31, 2017
Assets |  |  |  |  |
Contract assets and unbilled receivables | $ | 704,863 |  |  | $ | 2,850,274 |  |  | $ | 3,555,137 |
Inventory | 5,080,797 |  |  | (1,082,629 | ) |  | 3,998,168 |
Other assets | 3,842,068 |  |  | 400,000 |  |  | 4,242,068 |
Liabilities |  |  |  |  |
Contract liabilities and billings in excess of revenue earned | 1,555,883 |  |  | (891,737 | ) |  | 664,146 |
Stockholders’ equity |  |  |  |  |
Accumulated Deficit | $ | (240,121,901 | ) |  | $ | 3,059,382 |  |  | $ | (237,062,519 | )

In accordance with the new revenue standard requirements, the impact of adoption on the Company's condensed consolidated statement of operations was as follows:

| Three Months Ended September 29, 2018
Statement of Operations | As Reported |  | Balances Without Adoption of Topic 606 |  | Effect of Change Higher/(Lower)
Net product revenues | $ | 3,643,619 |  |  | $ | 3,878,651 |  |  | $ | (235,032 | )
Research and development revenues | 1,482,711 |  |  | 1,569,255 |  |  | (86,544 | )
Cost of product revenues | 3,659,800 |  |  | 3,497,549 |  |  | 162,251 |
Net loss attributable to Kopin Corporation | $ | (9,791,383 | ) |  | $ | (9,307,556 | ) |  | $ | (483,827 | )
| Nine Months Ended September 29, 2018
Statement of Operations | As Reported |  | Balances Without Adoption of Topic 606 |  | Effect of Change Higher/(Lower)
Net product revenues | $ | 13,160,507 |  |  | $ | 14,867,927 |  |  | $ | (1,707,420 | )
Research and development revenues | 3,563,341 |  |  | 3,822,973 |  |  | (259,632 | )
Cost of product revenues | 11,219,741 |  |  | 11,997,670 |  |  | (777,929 | )
Net loss attributable to Kopin Corporation | $ | (24,568,618 | ) |  | $ | (23,379,495 | ) |  | $ | (1,189,123 | )

See Note 13. Segments and Disaggregation of Revenue for additional information regarding the disaggregation of the Company's revenue by major source and the Company's updated accounting policy for revenue recognition.
11

Table of Contents
Contract Assets
Contract assets include unbilled amounts typically resulting from sales under contracts when the cost-to-cost method of revenue recognition is utilized and revenue recognized from customer arrangements, including licensing, exceeds the amount billed to the customer, and right to payment is not just subject to the passage of time. Amounts may not exceed their net realizable value. Contract assets are generally classified as current. The Company classifies the noncurrent portion of contract assets under other assets in its condensed consolidated balance sheets.
Contract Liabilities
Contract liabilities consist of advance payments and billings in excess of cost incurred and deferred revenue.
Performance Obligations
The Company's performance obligations that were satisfied at a point in time accounted for 63% and 91% of the Company's total revenue for the three months ended September 29, 2018 and September 30, 2017, respectively, and 63% and 88% of the Company's total revenue for the nine months ended September 29, 2018 and September 30, 2017, respectively. The Company's performance obligations that were satisfied over time accounted for 37% and 9% of the Company's total revenue for the three months ended September 29, 2018 and September 30, 2017, respectively, and 37% and 12% of the Company's total revenue for the nine months ended September 29, 2018 and September 30, 2017, respectively.
Remaining performance obligations represent the transaction price of orders for which work has not been performed and excludes unexercised contract options and potential orders under ordering-type contracts (e.g., indefinite-delivery, indefinite-quantity ("IDIQ")). As of September 29, 2018, the aggregate amount of the transaction price allocated to remaining performance obligations was $8.8 million. The Company expects to recognize revenue on the remaining performance obligations of $8.8 million over the next 12 months. The remaining performance obligations represent amounts to be earned under government contracts, which are subject to cancellation.

3. | CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES

The Company considers all highly liquid, short-term debt instruments with original maturities of three months or less to be cash equivalents.
Marketable debt securities consist primarily of commercial paper, medium-term corporate notes, and U.S. government and agency backed securities. The Company classifies these marketable debt securities as available-for-sale at fair value in “Marketable debt securities, at fair value.” The Company records the amortization of premium and accretion of discounts on marketable debt securities in the results of operations.
12

Table of Contents
The Company uses the specific identification method as a basis for determining cost and calculating realized gains and losses with respect to marketable debt securities. The gross gains and losses realized related to sales and maturities of marketable debt securities were not material during the three and nine months ended September 29, 2018 and the fiscal year ended December 30, 2017.
Investments in available-for-sale marketable debt securities were as follows at September 29, 2018 and December 30, 2017:

| Amortized Cost |  | Unrealized (Losses) Gains |  | Fair Value
| 2018 |  | 2017 |  | 2018 |  | 2017 |  | 2018 |  | 2017
U.S. government and agency backed securities | $ | 16,070,511 |  |  | $ | 35,014,593 |  |  | $ | (414,404 | ) |  | $ | (288,782 | ) |  | $ | 15,656,107 |  |  | $ | 34,725,811 |
Corporate debt | 11,178,825 |  |  | 8,988,608 |  |  | 1,036 |  |  | (7,702 | ) |  | 11,179,861 |  |  | 8,980,906 |
Certificates of deposit | — |  |  | 201,000 |  |  | — |  |  | (260 | ) |  | — |  |  | 200,740 |
Total | $ | 27,249,336 |  |  | $ | 44,204,201 |  |  | $ | (413,368 | ) |  | $ | (296,744 | ) |  | $ | 26,835,968 |  |  | $ | 43,907,457 |

The contractual maturity of the Company’s marketable debt securities was as follows at September 29, 2018:

| Less than One year |  | One to Five years |  | Greater than Five years |  | Total
U.S. government and agency backed securities | $ | 6,223,207 |  |  | $ | 9,432,900 |  |  | $ | — |  |  | $ | 15,656,107 |
Corporate debt | 3,213,495 |  |  | 7,966,366 |  |  | — |  |  | 11,179,861 |
Total | $ | 9,436,702 |  |  | $ | 17,399,266 |  |  | $ | — |  |  | $ | 26,835,968 |

The Company conducts a review of its marketable debt securities on a quarterly basis for the presence of other-than-temporary impairment ("OTTI"). The Company assesses whether OTTI is present when the fair value of a debt security is less than its amortized cost basis at the balance sheets date. Under these circumstances OTTI is considered to have occurred if (1) the Company intends to sell the security before recovery of its amortized cost basis; (2) it is “more likely than not” the Company will be required to sell the security before recovery of its amortized cost basis; or (3) the present value of expected cash flows is not sufficient to recover the entire amortized cost basis.
The Company further estimates the amount of OTTI resulting from a decline in the creditworthiness of the issuer (credit-related OTTI) and the amount of non credit-related OTTI. Non-credit-related OTTI can be caused by such factors as market illiquidity. Credit-related OTTI is recognized in earnings while non-credit-related OTTI on securities not expected to be sold is recognized in other comprehensive income (loss). The Company did not record OTTI for the three and nine months ended September 29, 2018 and September 30, 2017.
13

Table of Contents

4. | FAIR VALUE MEASUREMENTS

Financial instruments are categorized as Level 1, Level 2 or Level 3 based upon the method by which their fair value is computed. An investment is categorized as Level 1 when its fair value is based on unadjusted quoted prices in active markets for identical assets that the Company has the ability to access at the measurement date. An investment is categorized as Level 2 if its fair market value is based on quoted market prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, based on observable inputs such as interest rates, yield curves, or derived from or corroborated by observable market data by correlation or other means. An investment is categorized as Level 3 if its fair value is based on assumptions developed by the Company about what a market participant would use in pricing the assets.
The following table details the fair value measurements of the Company’s financial assets:

|  |  | Fair Value Measurement September 29, 2018 Using:
| Total |  | Level 1 |  | Level 2 |  | Level 3
Cash and Cash Equivalents | $ | 19,367,048 |  |  | $ | 19,367,048 |  |  | $ | — |  |  | $ | — |
U.S. Government Securities | 15,656,107 |  |  | 998,100 |  |  | 14,658,007 |  |  | — |
Corporate Debt | 11,179,861 |  |  | — |  |  | 11,179,861 |  |  | — |
GCS Holdings | 307,644 |  |  | 307,644 |  |  | — |  |  | — |
Equity Investments | 5,572,816 |  |  | — |  |  | — |  |  | 5,572,816 |
| $ | 52,083,476 |  |  | $ | 20,672,792 |  |  | $ | 25,837,868 |  |  | $ | 5,572,816 |
|  |  | Fair Value Measurement December 30, 2017 Using:
| Total |  | Level 1 |  | Level 2 |  | Level 3
Cash and Cash Equivalents | $ | 24,848,227 |  |  | $ | 24,848,227 |  |  | $ | — |  |  | $ | — |
U.S. Government Securities | 34,725,811 |  |  | 6,927,323 |  |  | 27,798,488 |  |  | — |
Corporate Debt | 8,980,906 |  |  | — |  |  | 8,980,906 |  |  | — |
Certificates of Deposit | 200,740 |  |  | — |  |  | 200,740 |  |  | — |
GCS Holdings | 478,546 |  |  | 478,546 |  |  | — |  |  | — |
Warrant | 2,000,000 |  |  | — |  |  | — |  |  | 2,000,000 |
| $ | 71,234,230 |  |  | $ | 32,254,096 |  |  | $ | 36,980,134 |  |  | $ | 2,000,000 |

Transfers between levels of the fair value hierarchy are reported at the beginning of the reporting period in which they occur. Changes in Level 3 investments were as follows:

| December 30, 2017 |  | Net unrealized losses |  | Purchases, issuances and settlements |  | Transfers in and or out of Level 3 |  | September 29, 2018
Equity Investments | $ | — |  |  | $ | (277,000 | ) |  | $ | 5,849,816 |  |  | $ | — |  |  | $ | 5,572,816 |
Warrant | 2,000,000 |  |  | (50,184 | ) |  | (1,949,816 | ) |  | — |  |  | — |
| $ | 2,000,000 |  |  | $ | (327,184 | ) |  | $ | 3,900,000 |  |  | $ | — |  |  | $ | 5,572,816 |

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of their short-term nature. If accrued liabilities were carried at fair value, these would be classified as Level 2 in the fair value hierarchy.
Marketable Debt Securities
The corporate debt consists of floating rate notes with a maturity that is over multiple years but has interest rates that are reset every three months based on the then-current three-month London Interbank Offering Rate ("three-month Libor"). The Company validates the fair market values of the financial instruments above by using discounted cash flow models, obtaining independent pricing of the securities or through the use of a model that incorporates the three-month Libor, the credit default swap rate of the issuer and the bid and ask price spread of the same or similar investments which are traded on several markets.
Warrant
The Company had a warrant to acquire up to 15% of the next round of equity offered by a customer as part of the licensing of technology to the customer. The Company exercised the warrant in April 2018.
14

Table of Contents
Equity Investments
The Company adopted ASU No. 2016-01 and the related amendments on December 31, 2017 (the first day of the Company's fiscal year 2018). This standard amends various aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The Company adopted the measurement alternative for equity investments without readily determinable fair values (often referred to as cost method investments) on a prospective basis. As a result, these investments will be revalued upon occurrence of an observable price change for similar investments and for impairments. See Note 8. Equity Investments for additional information regarding the Company's equity investments.

5. | INVENTORY

Inventories are stated at standard cost adjusted to approximate the lower of cost (first-in, first-out method) or net realizable value and consist of the following at September 29, 2018 and December 30, 2017:

| September 29, 2018 |  | December 30, 2017
Raw materials | $ | 2,438,941 |  |  | $ | 2,070,153 |
Work-in-process | 1,263,099 |  |  | 1,829,805 |
Finished goods | 1,251,868 |  |  | 1,180,839 |
| $ | 4,953,908 |  |  | $ | 5,080,797 |

6. | NET LOSS PER SHARE

Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period less any unvested restricted shares. Diluted net loss per share is calculated using weighted-average shares outstanding and contingently issuable shares, less weighted-average shares reacquired during the period. The net outstanding shares are adjusted for the dilutive effect of shares issuable upon the assumed conversion of the Company’s common stock equivalents, which consist of unvested restricted stock.
The following were not included in weighted-average common shares outstanding-diluted because they are anti-dilutive or performance conditions have not been met at the end of the period:

| Three Months Ended |  | Nine Months Ended
| September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Non-vested restricted common stock | 3,476,249 |  |  | 2,968,874 |  |  | 3,476,249 |  |  | 2,968,874 |

7. | STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION

Non-Vested Restricted Common Stock
The fair value of non-vested restricted common stock awards is generally the market value of the Company’s common stock on the date of grant. The non-vested restricted common stock awards require the employee to fulfill certain obligations, including remaining employed by the Company for one, two or four years (the vesting period) and in certain cases also require meeting either performance criteria or the Company’s stock achieving a certain price. For non-vested restricted common stock awards that solely require the recipient to remain employed with the Company, the stock compensation expense is amortized over the anticipated service period. For non-vested restricted common stock awards that require the achievement of performance criteria, the Company reviews the probability of achieving the performance goals on a periodic basis. If the Company determines that it is probable that the performance criteria will be achieved, the amount of compensation cost derived for the performance goal is amortized over the anticipated service period. If the performance criteria are not met, no compensation cost is recognized and any previously recognized compensation cost is reversed.
15

Table of Contents
Restricted stock activity was as follows:

| Shares |  | Weighted Average Grant Fair Value
Balance, December 30, 2017 | 2,629,274 |  |  | $ | 3.31 |
Granted | 1,549,000 |  |  | 2.25 |
Forfeited | (622,025 | ) |  | 4.13 |
Vested | (80,000 | ) |  | 3.64 |
Balance, September 29, 2018 | 3,476,249 |  |  | $ | 2.69 |

On December 31, 2017, the Company amended the employment agreement with our CEO, Dr. John Fan, to expire on December 31, 2020 and as part of the amendment issued restricted stock grants. Of the restricted stock grants issued to Dr. Fan, 640,000 shares will vest upon the first 20 consecutive trading day period following the grant date during which the Company's common stock trades at a price equal to or greater than $5.25, 150,000 shares will vest at the end of the first 20 consecutive trading day period following the grant date during which the Company’s common stock trades at a price per share equal to or greater than $6.00, and 150,000 shares will vest at the end of the first 20 consecutive trading day period following the grant date during which the Company’s common stock trades at a price per share equal to or greater than $7.00. All of the grants are subject to certain acceleration events and expire on December 31, 2020. The total fair value of these awards on December 31, 2017 was $1.7 million. The value of restricted stock grants that vest based on market conditions is computed on the date of grant using the Monte Carlo model with the following assumptions:

| For the period ended September 29, 2018
Performance price target | $ | 5.25 |  |  | $ | 6.00 |  |  | $ | 7.00 |
Expected volatility | 48.3 | % |  | 48.3 | % |  | 48.3 | %
Interest rate | 1.97 | % |  | 1.97 | % |  | 1.97 | %
Expected life (years) | 3 |  |  | 3 |  |  | 3 |
Dividend yield | — | % |  | — | % |  | — | %

Stock-Based Compensation
The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the three and nine months ended September 29, 2018 and September 30, 2017 (no tax benefits were recognized):

| Three Months Ended |  | Nine Months Ended
| September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Cost of product revenues | $ | 52,368 |  |  | $ | 142,604 |  |  | $ | 318,519 |  |  | $ | 405,778 |
Research and development | 159,436 |  |  | 203,288 |  |  | 627,519 |  |  | 616,500 |
Selling, general and administrative | 979,026 |  |  | 676,137 |  |  | 2,932,581 |  |  | 1,967,879 |
Total | $ | 1,190,830 |  |  | $ | 1,022,029 |  |  | $ | 3,878,619 |  |  | $ | 2,990,157 |

Unrecognized compensation expense for non-vested restricted common stock as of September 29, 2018 totaled $4.6 million and is expected to be recognized over a weighted average period of approximately two years.

8. | EQUITY INVESTMENTS

The Company acquired an equity interest in a company in the first quarter of 2018. The Company made a $1.0 million capital contribution during the three months ended March 31, 2018. The Company also contributed certain intellectual property. As of September 29, 2018, the Company owns 12.5% interest in this investment and the carrying value of the Company's investment is $3.9 million. The Company recorded a $0.3 million unrealized loss in the nine months ended September 29, 2018 in this equity investment due to a fluctuation in the foreign exchange rate. The fair value of this equity investment is approximately $3.6 million.
16

Table of Contents
The Company acquired an interest in an equity investment by exercising a warrant to acquire up to 15% of the next round of equity offered by a customer as part of the licensing of technology to the customer. The Company used the customer's capital structure, pricing of the shares being offered and 15% from the customer's qualified financing round in determining the value of its equity investment. The Company recorded an unrealized loss of less than $0.1 million in the nine months ended September 29, 2018 in this equity investment due to a change in the Company's estimate of the value of the equity investment based on the observable transaction price at the exercise date of the warrant. The fair value of this equity investment is approximately $1.9 million.
The Company adopted the measurement alternative for equity investments without readily determinable fair values (often referred to as cost method investments) on a prospective basis. As a result, these investments will be revalued upon occurrence of an observable price change for similar investments and for impairments. The Company did not have an observable price change for similar investments of its equity investments and recorded no impairments on its equity investments during the three months ended September 29, 2018.

9. | ACCRUED WARRANTY

The Company typically warrants its products against defect for 12 to 18 months, however, for certain products a customer may purchase an extended warranty. A provision for estimated future costs and estimated returns for credit relating to such warranty is recorded in the period when product is shipped and revenue recognized, and is updated as additional information becomes available. The Company’s estimate of future costs to satisfy warranty obligations is based primarily on historical warranty expense experienced and a provision for potential future product failures. Changes in the accrued warranty for the nine months ended September 29, 2018 were as follows:

Balance, December 30, 2017 | $ | 649,000 |
Additions | 120,000 |
Claims | (182,000 | )
Balance, September 29, 2018 | $ | 587,000 |

Extended Warranties
Deferred revenue represents the purchase of extended warranties by the Company's customers. The Company recognizes revenue from an extended warranty on the straight-line method over the life of the extended warranty, which is typically 12 to 15 months beyond the standard 12 to 18 month warranty. The Company classifies the current portion of deferred revenue under Other accrued liabilities in its condensed consolidated balance sheets. The Company currently has $0.5 million of deferred revenue related to extended warranties.
17

Table of Contents

10. | INCOME TAXES

The Company recorded a tax benefit of approximately $0.3 million and $0.1 million for the three months and nine months ended September 29, 2018, respectively. The tax benefit for the three months and nine months ended September 29, 2018 was due to a change in estimate related to deferred tax liabilities for the Company's withholding tax on future repatriated earnings from the Company's Korean subsidiary. The Company’s tax benefit of approximately $1.1 million for the nine months ended September 30, 2017, represents the net benefit of $0.1 million for foreign income taxes including loss carryback to 2016, uncertain tax positions and a benefit for the net reduction in estimated foreign withholding. In addition, as a result of the acquisition of NVIS, Inc. in the first quarter of 2017, we recognized $1.0 million of deferred tax liabilities, which provided evidence of recoverability of our net deferred tax assets that previously carried a full valuation allowance. We reduced the valuation allowance on our net deferred tax assets in the amount of $1.0 million and such reduction was recognized as a benefit for income taxes for the nine months ended September 30, 2017. As of September 29, 2018, the Company has available for tax purposes U.S. federal NOLs of approximately $184.0 million expiring 2022 through 2037. The Company has recognized a full valuation allowance on its domestic and certain foreign net deferred tax assets due to the uncertainty of realization of such assets.
Ownership changes, as defined by the Internal Revenue Code, may substantially limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income. The ownership change of NVIS, Inc. in 2017 did not result in an annual net operating loss limitation as the acquired entity was an S Corporation and did not have loss carryforwards. Subsequent ownership changes could affect the limitation in future years. Such annual limitations could result in the expiration of net operating loss and tax credit carryforwards before utilization.
The tax years 2001 through 2016 remain open to examination by major taxing jurisdictions where the Company is subject to United States federal tax. These periods have carryforward attributes generated in years past that may still be adjusted upon examination by the Internal Revenue Service or state tax authorities if they have or will be used in a future period. State statutes are generally shorter with shorter carryforward periods. The Company is currently not under examination by the Internal Revenue Service and is currently under examination by Massachusetts for the 2013 tax year. The Company recognizes both accrued interest and penalties related to its uncertain tax positions related to intercompany loan interest and potential transfer pricing exposure related to its Korean subsidiary.
The Company is in the process of dissolving and repatriating the unremitted earnings of its Korean subsidiary. As such, it accrues U.S. tax for the possible future repatriation of these unremitted foreign earnings. If the Company were to repatriate these earnings, it expects to have foreign withholding at a rate of 16.5% and does not expect any taxes to be paid in the U.S. when repatriated as it currently is expected to be a return of capital.

11. | GOODWILL AND INTANGIBLES

A rollforward of the Company's goodwill by segment is as follows:

| Kopin |  | Industrial |  | Total
Balance, December 30, 2017 | $ | 891,683 |  |  | $ | 888,564 |  |  | $ | 1,780,247 |
Change due to exchange rate fluctuations | (19,111 | ) |  | — |  |  | (19,111 | )
Balance, September 29, 2018 | $ | 872,572 |  |  | $ | 888,564 |  |  | $ | 1,761,136 |

The Company recognized $0.2 million and $0.5 million of amortization expense for the three months ended September 29, 2018 and September 30, 2017, respectively, and $0.7 million and $1.1 million of amortization expense for the nine months ended September 29, 2018 and September 30, 2017, respectively, related to intangible assets. At September 29, 2018 and December 30, 2017, the Company's intangible assets include customer relationships, developed technology and a trade name, which had a total carrying value of $2.5 million, total accumulated amortization of $2.2 million and $1.6 million, respectively, and a total net book value of $0.2 million and $0.9 million, respectively. The intangibles have a remaining life of less than one year as of September 29, 2018.
18

Table of Contents
12. CONTRACT ASSETS AND LIABILITIES
Net contract assets (liabilities) consisted of the following:

| September 29, 2018 |  | December 30, 2017 |  | $ Change |  | % Change
Contract assets—current | $ | 1,935,262 |  |  | $ | 704,863 |  |  | $ | 1,230,399 |  |  | 175 | %
Contract assets—noncurrent | 400,000 |  |  | — |  |  | 400,000 |  |  | — | %
Contract liabilities—current | (428,642 | ) |  | (1,181,712 | ) |  | 753,070 |  |  | (64 | )%
Contract liabilities—noncurrent | (154,769 | ) |  | (374,171 | ) |  | 219,402 |  |  | (59 | )%
Net contract assets (liabilities) | $ | 1,751,851 |  |  | $ | (851,020 | ) |  | $ | 2,602,871 |  |  | (306 | )%

The $2.6 million increase in the Company's net contract assets (liabilities) from December 30, 2017 to September 29, 2018 was primarily due to the adoption of Topic 606.
In the three and nine months ended September 29, 2018, the Company recognized revenue of less than $0.1 million and $0.2 million, respectively, related to our contract liabilities at December 31, 2017. In the three and nine months ended September 30, 2017, the Company recognized revenue of $0.1 million and $0.3 million, respectively, related to our contract liabilities at January 1, 2017.
The Company did not recognize impairment losses on our contract assets in the three and nine months ended September 29, 2018 and September 30, 2017.
13. SEGMENTS AND DISAGGREGATION OF REVENUE
The Company’s chief operating decision maker is its Chief Executive Officer. The Company has determined it has two reportable segments: Industrial, which includes the operations that develop and manufacture its reflective display products and virtual reality systems for test and simulation products, and Kopin, which includes the operations that develop and manufacture its other products.
As noted in Note 2. Accounting Standards, effective December 31, 2017, the Company adopted Topic 606 using the modified retrospective method. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.
19

Table of Contents
Segment financial results were as follows:

| Three Months Ended |  | Nine Months Ended
Total Revenue (in thousands) | September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Kopin | $ | 3,629 |  |  | $ | 3,744 |  |  | $ | 11,033 |  |  | $ | 10,409 |
Industrial | 1,895 |  |  | 2,395 |  |  | 6,549 |  |  | 6,036 |
Eliminations | (398 | ) |  | — |  |  | (858 | ) |  | — |
Total | $ | 5,126 |  |  | $ | 6,139 |  |  | $ | 16,724 |  |  | $ | 16,445 |
| Three Months Ended |  | Nine Months Ended
Total Intersegment Revenue (in thousands) | September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Kopin | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Industrial | 398 |  |  | — |  |  | 858 |  |  | — |
Total | $ | 398 |  |  | $ | — |  |  | $ | 858 |  |  | $ | — |
| Three Months Ended |  | Nine Months Ended
Net Loss Attributable to Kopin (in thousands) | September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Kopin | $ | (9,814 | ) |  | $ | (8,117 | ) |  | $ | (24,650 | ) |  | $ | (23,170 | )
Industrial | 23 |  |  | (130 | ) |  | 81 |  |  | (268 | )
Total | $ | (9,791 | ) |  | $ | (8,247 | ) |  | $ | (24,569 | ) |  | $ | (23,438 | )
Total Assets (in thousands) |  |  |  |  | September 29, 2018 |  | December 30, 2017
Kopin |  |  |  |  | $ | 62,573 |  |  | $ | 82,707 |
Industrial |  |  |  |  | 9,052 |  |  | 8,615 |
Total |  |  |  |  | $ | 71,625 |  |  | $ | 91,322 |

Total long-live assets by country at September 29, 2018 and December 30, 2017 were:

Total Long-lived Assets (in thousands) | September 29, 2018 |  | December 30, 2017
U.S. | $ | 2,103 |  |  | $ | 2,456 |
United Kingdom | 228 |  |  | 192 |
China | 2,575 |  |  | 338 |
Japan | 142 |  |  | 206 |
Korea | 28 |  |  | 1,885 |
Total | $ | 5,076 |  |  | $ | 5,077 |

We disaggregate our revenue from contracts with customers by geographic location and by display application, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.
20

Table of Contents
During the three and nine months ended September 29, 2018 and September 30, 2017, the Company derived its sales from the following geographies:

| Three Months Ended September 29, 2018
| Kopin |  | Industrial |  | Total
(In thousands, except percentages) | Revenue |  | % of Total |  | Revenue |  | % of Total |  | Revenue |  | % of Total
United States | $ | 2,427 |  |  | 47 | % |  | $ | 820 |  |  | 16 | % |  | $ | 3,247 |  |  | 63 | %
Other Americas | 14 |  |  | — |  |  | 6 |  |  | — |  |  | 20 |  |  | — |
Total Americas | 2,441 |  |  | 48 |  |  | 826 |  |  | 16 |  |  | 3,267 |  |  | 64 |
Asia-Pacific | 863 |  |  | 17 |  |  | 324 |  |  | 6 |  |  | 1,187 |  |  | 23 |
Europe | 325 |  |  | 6 |  |  | 341 |  |  | 7 |  |  | 666 |  |  | 13 |
Other | — |  |  | — |  |  | 6 |  |  | — |  |  | 6 |  |  | — |
Total Revenues | $ | 3,629 |  |  | 71 | % |  | $ | 1,497 |  |  | 29 | % |  | $ | 5,126 |  |  | 100 | %
| Three Months Ended September 30, 2017
| Kopin |  | Industrial |  | Total
(In thousands, except percentages) | Revenue |  | % of Total |  | Revenue |  | % of Total |  | Revenue |  | % of Total
United States | $ | 2,000 |  |  | 33 | % |  | $ | 886 |  |  | 14 | % |  | $ | 2,886 |  |  | 47 | %
Other Americas | 3 |  |  | — |  |  | — |  |  | — |  |  | 3 |  |  | — |
Total Americas | 2,003 |  |  | 33 |  |  | 886 |  |  | 14 |  |  | 2,889 |  |  | 47 |
Asia-Pacific | 1,200 |  |  | 20 |  |  | 168 |  |  | 3 |  |  | 1,368 |  |  | 22 |
Europe | 541 |  |  | 9 |  |  | 1,341 |  |  | 22 |  |  | 1,882 |  |  | 31 |
Total Revenues | $ | 3,744 |  |  | 61 | % |  | $ | 2,395 |  |  | 39 | % |  | $ | 6,139 |  |  | 100 | %
| Nine Months Ended September 29, 2018
| Kopin |  | Industrial |  | Total
(In thousands, except percentages) | Revenue |  | % of Total |  | Revenue |  | % of Total |  | Revenue |  | % of Total
United States | $ | 7,586 |  |  | 45 | % |  | $ | 2,814 |  |  | 17 | % |  | $ | 10,400 |  |  | 62 | %
Other Americas | 43 |  |  | 1 |  |  | 29 |  |  | — |  |  | 72 |  |  | 1 |
Total Americas | 7,629 |  |  | 46 |  |  | 2,843 |  |  | 17 |  |  | 10,472 |  |  | 63 |
Asia-Pacific | 2,331 |  |  | 14 |  |  | 1,484 |  |  | 9 |  |  | 3,815 |  |  | 23 |
Europe | 1,073 |  |  | 6 |  |  | 1,336 |  |  | 8 |  |  | 2,409 |  |  | 14 |
Other | — |  |  | — |  |  | 28 |  |  | — |  |  | 28 |  |  | — |
Total Revenues | $ | 11,033 |  |  | 66 | % |  | $ | 5,691 |  |  | 34 | % |  | $ | 16,724 |  |  | 100 | %
| Nine Months Ended September 30, 2017
| Kopin |  | Industrial |  | Total
(In thousands, except percentages) | Revenue |  | % of Total |  | Revenue |  | % of Total |  | Revenue |  | % of Total
United States | $ | 6,166 |  |  | 37 | % |  | $ | 1,742 |  |  | 11 | % |  | $ | 7,908 |  |  | 48 | %
Other Americas | 13 |  |  | — |  |  | 22 |  |  | — |  |  | 35 |  |  | — |
Total Americas | 6,179 |  |  | 37 |  |  | 1,764 |  |  | 11 |  |  | 7,943 |  |  | 48 |
Asia-Pacific | 2,800 |  |  | 17 |  |  | 1,349 |  |  | 8 |  |  | 4,149 |  |  | 25 |
Europe | 1,430 |  |  | 9 |  |  | 2,915 |  |  | 18 |  |  | 4,345 |  |  | 27 |
Other | — |  |  | — |  |  | 8 |  |  | — |  |  | 8 |  |  | — |
Total Revenues | $ | 10,409 |  |  | 63 | % |  | $ | 6,036 |  |  | 37 | % |  | $ | 16,445 |  |  | 100 | %

21

Table of Contents
During the three and nine months ended September 29, 2018 and September 30, 2017, the Company derived its sales from the following display applications:

| Three Months Ended September 29, 2018 |  | Three Months Ended September 30, 2017
(In thousands) | Kopin |  | Industrial |  | Total |  | Kopin |  | Industrial |  | Total
Military | $ | 582 |  |  | $ | 917 |  |  | $ | 1,499 |  |  | $ | 913 |  |  | $ | 1,872 |  |  | $ | 2,785 |
Industrial | 721 |  |  | 562 |  |  | 1,283 |  |  | 657 |  |  | 519 |  |  | 1,176 |
Consumer | 816 |  |  | — |  |  | 816 |  |  | 1,282 |  |  | — |  |  | 1,282 |
R&D | 1,482 |  |  | 1 |  |  | 1,483 |  |  | 550 |  |  | — |  |  | 550 |
Other | 28 |  |  | 17 |  |  | 45 |  |  | 342 |  |  | 4 |  |  | 346 |
Total Revenues | $ | 3,629 |  |  | $ | 1,497 |  |  | $ | 5,126 |  |  | $ | 3,744 |  |  | $ | 2,395 |  |  | $ | 6,139 |
| Nine Months Ended September 29, 2018 |  | Nine Months Ended September 30, 2017
(In thousands) | Kopin |  | Industrial |  | Total |  | Kopin |  | Industrial |  | Total
Military | $ | 2,448 |  |  | $ | 2,972 |  |  | $ | 5,420 |  |  | $ | 2,721 |  |  | $ | 3,637 |  |  | $ | 6,358 |
Industrial | 1,941 |  |  | 2,320 |  |  | 4,261 |  |  | 1,765 |  |  | 2,321 |  |  | 4,086 |
Consumer | 3,213 |  |  | — |  |  | 3,213 |  |  | 2,811 |  |  | — |  |  | 2,811 |
R&D | 3,363 |  |  | 200 |  |  | 3,563 |  |  | 1,934 |  |  | 9 |  |  | 1,943 |
Other | 68 |  |  | 199 |  |  | 267 |  |  | 1,178 |  |  | 69 |  |  | 1,247 |
Total Revenues | $ | 11,033 |  |  | $ | 5,691 |  |  | $ | 16,724 |  |  | $ | 10,409 |  |  | $ | 6,036 |  |  | $ | 16,445 |

14. | LITIGATION

The Company may engage in legal proceedings arising in the ordinary course of business. Claims, suits, investigations and proceedings are inherently uncertain and it is not possible to predict the ultimate outcome of such matters and our business, financial condition, results of operations or cash flows could be affected in any particular period.
BlueRadios, Inc. v. Kopin Corporation, Civil Action No. 16-02052-JLK (D. Col.):
On August 12, 2016, BlueRadios, Inc. ("BlueRadios") filed a complaint in the U.S. District Court for the District of Colorado, alleging that the Company breached a contract between it and BlueRadios concerning a joint venture between the Company and BlueRadios to design, develop and commercialize micro-display products with embedded wireless technology referred to as “Golden-i” breached the covenant of good faith and fair dealing associated with that contract, breached its fiduciary duty to BlueRadios, and misappropriated trade secrets owned by BlueRadios in violation of Colorado law (C.R.S. § 7-74-104(4)) and the Defend Trade Secrets Act (18 U.S.C. § 1836(b)(1)). BlueRadios further alleges that the Company was unjustly enriched by its alleged misconduct, BlueRadios is entitled to an accounting to determine the amount of profits obtained by the Company as a result of its alleged misconduct, and the inventorship on at least ten patents or patent applications owned by the Company need to be corrected to list BlueRadios’ employees as inventors and thereby list BlueRadios as co-assignees of the patents. BlueRadios seeks monetary, declaratory, and injunctive relief.
On October 11, 2016, the Company filed its Answer and Affirmative Defenses. The parties are in the midst of discovery, with the close of all discovery currently set for March 14, 2019. A trial date has not yet been set by the Court. The Company has not concluded a loss from this matter is probable; therefore, we have not recorded an accrual for litigation or claims related to this matter for the period ended September 29, 2018. The Company will continue to evaluate information as it becomes known and will record an estimate for losses at the time or times when it is both probable that a loss has been incurred and the amount of the loss is reasonably estimable.
15. RELATED PARTY TRANSACTIONS
The Company may from time to time enter into agreements with stockholders, affiliates and other companies engaged in certain aspects of the display, electronics, optical and software industries as part of our business strategy. In addition, the wearable computing product market is relatively new and there may be other technologies the Company needs to purchase from affiliates to enhance its product offering.
22

Table of Contents
During the three and nine month periods ended September 29, 2018 and September 30, 2017, the Company had the following transactions with related parties:

| Three Months Ended
| September 29, 2018 |  | September 30, 2017
| Sales |  | Purchases |  | Sales |  | Purchases
Goertek | $ | — |  |  | $ | 90,594 |  |  | $ | — |  |  | $ | 207,694 |
RealWear, Inc. | 634,834 |  |  | — |  |  | 48,320 |  |  | — |
| $ | 634,834 |  |  | $ | 90,594 |  |  | $ | 48,320 |  |  | $ | 207,694 |
| Nine Months Ended
| September 29, 2018 |  | September 30, 2017
| Sales |  | Purchases |  | Sales |  | Purchases
Goertek | $ | — |  |  | $ | 389,503 |  |  | $ | — |  |  | $ | 390,619 |
RealWear, Inc. | 1,147,789 |  |  | — |  |  | 109,952 |  |  | — |
| $ | 1,147,789 |  |  | $ | 389,503 |  |  | $ | 109,952 |  |  | $ | 390,619 |

The Company had the following receivables, contract assets and payables with related parties:

| September 29, 2018 |  | December 30, 2017
| Receivables |  | Total contract assets |  | Payables |  | Receivables |  | Payables
Goertek | $ | — |  |  | $ | — |  |  | $ | 145,538 |  |  | $ | — |  |  | $ | 326,877 |
RealWear, Inc. | 589,358 |  |  | 900,000 |  |  | — |  |  | 414,635 |  |  | — |
| $ | 589,358 |  |  | $ | 900,000 |  |  | $ | 145,538 |  |  | $ | 414,635 |  |  | $ | 326,877 |

23

Table of Contents

Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements made relating to our expectation that we will have negative cash flow from operating activities in 2018; our intention to continue to pursue U.S. government development contracts for applications that relate to our commercial product applications; our belief that it is important to retain personnel with experience and expertise relevant to our business; our belief that it is important to invest in research and development to achieve profitability even during periods when we are not profitable; our belief that our wearable technology will be embraced by consumers and commercial users; our belief that our ability to develop and expand our wearable technologies and to market and license our concept systems and components will be critical for our revenue growth, positive cash flow, and profitability; our belief that a strengthening of the U.S. dollar could increase the price of our products in foreign markets; our expectation that the impact of the adoption of the new standard, ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), will be material to the Company's revenues on an ongoing basis; our expectation that our revenues for the fiscal year 2018 will be in the range of $24.5 million to $26.5 million; our belief that our future success will depend primarily upon the technical expertise, creative skills and management abilities of our officers and key employees rather than on patent ownership; our belief that our extensive portfolio of patents, trade secrets and non-patented know-how provides us with a competitive advantage in the wearable technologies market; our expectation not to pay cash dividends for the foreseeable future and to retain earnings for the development of our businesses; our expectation that we will expend betwe en $1.0 million and $1.5 million on capital expenditures over the next twelve months; our belief that our available cash resources will support our operations and capital needs for at least the next twelve months; our expectation that we will incur taxes based on our foreign operations in 2018; our expectation that we will have a state tax provision in 2018; our statement that we do not have any immediate plans to repatriate the cash and marketable debt securities held in our foreign subsidiaries, other than Korea; our expectation that we would have foreign withholding at a rate of 16.5% if we were to repatriate foreign earnings from our Korean subsidiary and that no taxes would be paid in the U.S. upon repatriation as we currently expect such foreign earnings to be a return of capital; and our belief that the effect, if any, of reasonably possible near-term changes in interest rates on our financial position, results of operations, and cash flows should not be material. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industries in which we operate, management's beliefs, and assumptions made by management. In addition, other written or oral statements, which constitute forward-looking statements, may be made by or on our behalf. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “could,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements, whether as a result of new information, future events or otherwise. Factors that could cause or contribute to such differences in outcomes and results include, but are not limited to any of, those discussed below in Item 1A and those set forth in our other periodic filings filed with the SEC. Except as required by the federal securities laws, we do not intend to update any forward-looking statements even if new information becomes available or other events occur in the future.
Overview
We were incorporated in Delaware in 1984 and are a leading inventor, developer, manufacturer and seller of technologies, components and systems for the smart headset wearable, military, thermal imager, 3D optical inspection system and training and simulation markets.
We adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) effective December 31, 2017 (the first day of our fiscal year 2018) and applied the modified retrospective method. This update is discussed in the notes to the unaudited condensed consolidation financial statements within Item 1 of this Form 10-Q. All amounts and disclosures set forth in this Form 10-Q reflect these changes.
The following discussion should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 30, 2017 and our unaudited condensed consolidated financial statements included in this Form 10-Q.
Critical Accounting Policies Update
Our consolidated financial statements are based on the application of U.S. Generally Accepted Accounting Principles ("GAAP"), which require us to make estimates and assumptions about future events that affect the amounts reported in our unaudited consolidated financial statements and the accompanying notes. Further detail regarding our critical accounting policies can be found in “Item 7. Management Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 30, 2017. Significant changes to our critical accounting policies as a result of adoption of Topic 606 are discussed below:
24

Table of Contents
Revenue Recognition
Substantially all of our revenues are either derived from the sales of components for use in military applications or our wearable technology components that can be integrated to create industrial and consumer headset systems. We also have development contracts for the design, manufacture and modification of products for the U.S. government or a prime contractor for the U.S. government (“U.S. government”) or for a customer that sells into the industrial or consumer markets. The Company's contracts with the U.S. government are typically subject to the Federal Acquisition Regulations (“FAR”) and are priced based on estimated or actual costs of producing goods. The FAR provides guidance on the types of costs that are allowable in establishing prices for goods provided under U.S. government contracts. The pricing for non-U.S. government contracts is based on the specific negotiations with each customer.
Our fixed-price contracts with the U.S. government may result in revenue recognized in excess of amounts actually billed. We disclose the in excess of revenues over amounts actually billed as Contract assets and unbilled receivables on the balance sheet. Amounts billed and due from our customers are classified as Accounts receivable on the balance sheets. In some instances, the U.S. government retains a small portion of the contract price until completion of the contract. The portion of the payments retained until final contract settlement is not considered a significant financing component because the intent is to protect the customer. For contracts with the U.S. government, we typically receive interim payments either as work progresses, we achieve certain milestones or based on a schedule in the contract. We recognize a liability for these advance payments in excess of revenue recognized and present it as Contract liabilities and billings in excess of revenue earned on the balance sheets. The advanced payment typically is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. For industrial and consumer purchase orders, we typically receive payments within 30 to 60 days of shipments of the product, although for some purchase orders, we may require an advanced payment prior to shipment of the product.
To determine the proper revenue recognition method for complex contracts with the same customer, we evaluate whether two or more contracts should be combined and accounted for as one single contract and whether the combined or single contract should be accounted for as more than one performance obligation. This evaluation requires significant judgment and the decision to combine a group of contracts or separate the combined or single contract into multiple performance obligations could change the amount of revenue and profit recorded in a given period. For most of our development contracts and contracts with the U.S government, the customer contracts with us to provide a significant service of integrating a set of components into a single unit. Hence, the entire contract is accounted for as one performance obligation. Less common, however, we may promise to provide distinct goods or services within a contract in which case we separate the contract into more than one performance obligation. If a contract is separated into more than one performance obligation, we allocate the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. In cases where we sell standard products, the observable standalone sales are used to determine the standalone selling price.
The Company recognizes revenue from a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For certain contracts that meet the foregoing requirements, primarily international direct commercial and military sale contracts, we recognize revenue once we have obtained all regulatory approvals.
Commencing in 2018 for certain contracts with the U.S. government, the Company recognizes revenue over time as we perform because of continuous transfer of control to the customer and the lack of an alternative use for the product. The continuous transfer of control to the customer is supported by liability clauses in the contract that allow the U.S. government to unilaterally terminate the contract for convenience, pay us for costs incurred plus a reasonable profit and take control of any work in process. For contracts with commercial customers, while the contract may have a similar liability clause, our products historically have an alternative use and thus, revenue is recognized at a point in time.
In situations where control transfers over time, revenue is recognized based on the extent of progress towards completion of the performance obligation. We generally use the cost-to-cost approach to measure the extent of progress towards completion of the performance obligation for our contracts because we believe it best depicts the transfer of assets to the customer, which occurs as we incur costs on our contracts. Under the cost-to-cost measure approach, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. Revenues are recorded proportionally as costs are incurred.
Accounting for design, development and production contracts requires judgment relative to assessing risks, estimating contract revenues and costs, and making assumptions for schedule and technical issues. Due to the size and nature of the work required to be performed on many of our contracts, the estimation of total revenue and cost at completion is complicated and
25

Table of Contents
subject to many variables. Contract costs include material, labor and subcontracting costs, as well as an allocation of indirect costs. We have to make assumptions regarding the number of labor hours required to complete a task, the complexity of the work to be performed, the availability and cost of materials, and performance by our subcontractors. For contract change orders, claims or similar items, we apply judgment in estimating the amounts and assessing the potential for realization. These amounts are only included in contract value when they can be reliably estimated and realization is considered probable. If our estimate of total contract costs or our determination of whether the customer agrees that a milestone is achieved is incorrect, our revenue could be overstated or understated and the profits or loss reported could be wrong.
For our commercial customers, the Company's revenue is recognized when obligations under the terms of a contract with our customer is satisfied; generally this occurs with the transfer of control of the Company's products or services. Revenue is recorded as the amount of consideration we expect to receive in exchange for transferring goods or providing services. Provisions for product returns and allowances are recorded in the same period as the related revenues. We analyze historical returns, current economic trends and changes in customer demand and acceptance of product when evaluating the adequacy of sales returns and other allowances. Certain product sales are made to distributors under agreements allowing for a limited right of return on unsold products. Sales to distributors are primarily made for sales to the distributors' customers and not for stocking of inventory. We delay revenue recognition for our estimate of distributor claims of right of return on unsold products based upon our historical experience with our products and specific analysis of amounts subject to return based upon discussions with our distributors or their customers. Sales, value add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue.
The rights and benefits to the Company's intellectual property are conveyed to certain customers through technology license agreements. These agreements may include other performance obligations including the sale of product to the customer. When the license is distinct from other obligations in the agreement, the Company treats the license and other performance obligations as separate performance obligations. Accordingly, the license is recognized at a point in time or over time based on the standalone selling price. The sale of materials is recognized at a point in time, which occurs with the transfer of control of the Company's products or services. In certain instances, the Company is entitled to sales-based royalties under license agreements. These sales-based royalties are recognized when they are earned.
Results of Operations
As described in our "Forward-Looking Statements" on page 24 of this Form 10-Q, our interim period results of operations and period-to-period comparisons of such results may not be indicative of our future operating results. Additionally, we use a fiscal calendar, which may result in differences in the number of work days in the current and comparable prior interim periods and could affect period-to-period comparisons. The following discussions of comparative results among periods, including the discussion of segment results, should be viewed in this context.
Revenues. For the three and nine months ended September 29, 2018 and September 30, 2017, our revenues by display application, which include product sales and amounts earned from research and development contracts, were as follows:

| Three Months Ended |  | Nine Months Ended
(In thousands) | September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Military | $ | 1,499 |  |  | $ | 2,785 |  |  | $ | 5,420 |  |  | $ | 6,358 |
Industrial | 1,283 |  |  | 1,176 |  |  | 4,261 |  |  | 4,086 |
Consumer | 816 |  |  | 1,282 |  |  | 3,213 |  |  | 2,811 |
R&D | 1,483 |  |  | 550 |  |  | 3,563 |  |  | 1,943 |
Other | 45 |  |  | 346 |  |  | 267 |  |  | 1,247 |
Total Revenues | $ | 5,126 |  |  | $ | 6,139 |  |  | $ | 16,724 |  |  | $ | 16,445 |

Sales of our products for Military applications include systems used by the military both in the field and for training and simulation. The decrease in Military applications revenues in the three and nine months ended September 29, 2018 as compared to the three and nine months ended September 30, 2017 is primarily due to the completion of military programs at our subsidiary NVIS, Inc. ("NVIS"). This decrease was partially offset by an increase in revenue from virtual reality optical systems for simulation and training for the U.S. military.
Industrial applications revenue represents customers who purchase our display products for use in headsets used for applications in manufacturing, distribution, public safety, 3D metrology equipment and other industrial applications. Our 3D metrology customers are primarily located in Asia and they sell to Asian contract manufacturers who use the 3D metrology machines for quality control purposes. The increase in Industrial applications revenue for the three and nine months ended
26

Table of Contents
September 29, 2018 as compared to the three and nine months ended September 30, 2017 is primarily due to an increase in sales to customers who use our display components in industrial headsets.
Sales of our displays for Consumer applications is primarily for the use in thermal imaging products, recreational rifle and hand-held scopes and drone racing headsets. The decrease in Consumer applications for the three and nine months ended September 29, 2018 as compared to the three and nine months ended September 30, 2017 was primarily due to decreased demand for displays and components used in thermal imaging products and drone racing headsets.
R&D revenues increase d in the three and nine months ended September 29, 2018 as compared to the three and nine months ended September 30, 2017 primarily due to funding for U.S. military programs, including the Family of Weapon Sights ("FWS") program.
Historically, we have recognized revenue in the period when we have shipped units of products. For the fiscal year 2018, we adopted Topic 606 and certain revenues are being recorded on the percentage of completion method using a cost-to-cost approach. Prior to the adoption of Topic 606, we believe we would have recorded approximately $4.1 million as revenue, however, with our adoption of Topic 606 the approximately $4.1 million was recognized as part of the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The Company expects the impact of the adoption of the new standard to be material to the Company's revenues on an ongoing basis. Our expectation is that our revenues for the fiscal year 2018 will be in the range of $24.5 million to $26.5 million.
International sales represented 37% and 53% of product revenues for the three months ended September 29, 2018 and September 30, 2017, respectively, and 38% and 52% of product revenues for the nine months ended September 29, 2018 and September 30, 2017, respectively. Our international sales are primarily denominated in U.S. currency. Consequently, a strengthening of the U.S. dollar could increase the price in local currencies of our products in foreign markets and make our products relatively more expensive than competitors' products that are denominated in local currencies, which could lead to a reduction in sales or profitability in those foreign markets. We have not taken any protective measures against exchange rate fluctuations, such as purchasing hedging instruments with respect to such fluctuations, because of the historically stable exchange rate between the British Pound Sterling (the functional currency of our U.K. subsidiaries) and the U.S. dollar. Foreign currency translation impact on our results, if material, is described in further detail under "Item 3. Quantitative and Qualitative Disclosures About Market Risk" section below.
Cost of Product Revenues. Cost of product revenues, which is comprised of materials, labor and manufacturing overhead related to the production of our products for the three and nine months ended September 29, 2018 and September 30, 2017 were as follows:

| Three Months Ended |  | Nine Months Ended
(In thousands, except for percentages) | September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Cost of product revenues | $ | 3,660 |  |  | $ | 4,145 |  |  | $ | 11,220 |  |  | $ | 11,379 |
Cost of product revenues as a % of net product revenues | 100.4 | % |  | 74.2 | % |  | 85.3 | % |  | 78.5 | %

Cost of product revenues as a percentage of net product revenues in the three and nine months ended September 29, 2018 increased as compared to the three and nine months ended September 30, 2017. The decrease in cost of product revenues for the three and nine months ended September 29, 2018 as compared to the three and nine months ended September 30, 2017 was primarily due to a decrease in volumes from lower sales in the third quarter of 2018 and lower yields.
Research and Development. R&D expenses are incurred in support of internal display development programs or programs funded by agencies or prime contractors of the U.S. government and commercial partners. R&D costs include staffing, purchases of materials and laboratory supplies, circuit design costs, fabrication and packaging of display products, and overhead. In fiscal year 2018, we expect our R&D expenditures to be related to our display products, overlay weapon sights and Kopin Wearable technologies. Funded and internal R&D expense are combined in research and development expenses in the statement of operations. R&D expenses for the three and nine months ended September 29, 2018 and September 30, 2017
27

Table of Contents
were as follows:

| Three Months Ended |  | Nine Months Ended
(In thousands) | September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Funded | $ | 2,006 |  |  | $ | 765 |  |  | $ | 3,640 |  |  | $ | 2,383 |
Internal | 2,593 |  |  | 4,488 |  |  | 9,937 |  |  | 11,831 |
Total research and development expense | $ | 4,599 |  |  | $ | 5,253 |  |  | $ | 13,577 |  |  | $ | 14,214 |

Funded R&D expense for the three and nine months ended September 29, 2018 increased as compared to the three and nine months ended September 30, 2017 primarily due to an increase in funding for U.S. military programs, including the FWS program. For the three and nine months ended September 29, 2018, internal R&D decreased as compared to the three and nine months ended September 30, 2017 primarily due to products moving into the commercialization phase.
Selling, General and Administrative. Selling, general and administrative ("S,G&A") expenses consist of the expenses incurred by our sales and marketing personnel and related expenses, and administrative and general corporate expenses. S,G&A expenses for the three and nine months ended September 29, 2018 and September 30, 2017 were as follows:

| Three Months Ended |  | Nine Months Ended
(In thousands, except for percentages) | September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Selling, general and administration expense | $ | 7,166 |  |  | $ | 5,345 |  |  | $ | 21,011 |  |  | $ | 16,187 |
Selling, general and administration expense as a % of revenues | 139.8 | % |  | 87.1 | % |  | 125.6 | % |  | 98.4 | %

S,G&A increase d for the three and nine months ended September 29, 2018 as compared to the three and nine months ended months ended September 30, 2017 primarily due to an increase in compensation expenses including stock-based compensation, legal expenses, product advertising and patent maintenance cost.
Other Income, net. Other income, net, is primarily composed of interest income, foreign currency transaction and remeasurement gains and losses incurred by our Korean and U.K.-based subsidiaries and other non-operating income items. Other income, net, for the three and nine months ended September 29, 2018 and September 30, 2017 was as follows:

| Three Months Ended |  | Nine Months Ended
(In thousands) | September 29, 2018 |  | September 30, 2017 |  | September 29, 2018 |  | September 30, 2017
Other income, net | $ | 175 |  |  | $ | 306 |  |  | $ | 4,442 |  |  | $ | 691 |

During the three months ended September 29, 2018 and September 30, 2017, we recorded $0.2 million of foreign currency losses and $0.2 million of foreign currency gains, respectively. During the nine months ended September 29, 2018 and September 30, 2017, we recorded a $0.3 million and $0.4 million of foreign currency losses, respectively. During the nine months ended September 29, 2018 and September 30, 2017, we recorded a non-cash loss of less than $0.1 million and $0.3 million gain, respectively, on the mark-to-market of equity investments. During the nine months ended September 29, 2018, the Company recognized a gain of $2.9 million from the transfer of intellectual property in exchange for equity interest in an investment. During the nine months ended September 29, 2018, the Company received $1.0 million of insurance proceeds related to the embezzlement at our Korean subsidiary, which was discovered in 2016.
Tax Provision. The Company recorded a tax benefit of approximately $0.3 million and $0.1 million for the three months and nine months ended September 29, 2018, respectively. The tax benefit for the three months and nine months ended September 29, 2018 was due to a change in estimate related to deferred tax liabilities for the Company's withholding tax on future repatriated earnings from the Company's Korean subsidiary. The Company’s tax benefit of approximately $1.1 million for the nine months ended September 30, 2017, represents the net benefit of $0.1 million for foreign income taxes including loss carryback to 2016, uncertain tax positions and a benefit for the net reduction in estimated foreign withholding. In addition, as a result of the acquisition of NVIS, Inc. in the first quarter of 2017, we recognized $1.0 million of deferred tax liabilities which provided evidence of recoverability of our net deferred tax assets that previously carried a full valuation allowance. We reduced the valuation allowance on our net deferred tax assets in the amount of $1.0 million and such reduction was recognized as a benefit for income taxes for the nine months ended September 30, 2017.
Net Loss (Income) Attributable to Noncontrolling Interest. As of September 29, 2018 and September 30, 2017, we owned approximately 93% of the equity of our Korean subsidiary, Kowon, and 80% of the equity of eMDT America ("eMDT"). Net loss (income) attributable to noncontrolling interest on our consolidated statement of operations represents the portion of the
28

Table of Contents
results of operations of our majority owned subsidiaries which is allocated to the stockholders of the equity interests not owned by us. The change in net loss (income) attributable to noncontrolling interest is the result of the change in the results of operations of Kowon and eMDT for the three and nine months ended September 29, 2018 and September 30, 2017.
Liquidity and Capital Resources
At September 29, 2018 and December 30, 2017, we had cash and cash equivalents and marketable securities of $46.2 million and $68.8 million, respectively, and working capital of $46.8 million and $67.6 million at September 29, 2018 and December 30, 2017, respectively. The change in cash and cash equivalents and marketable securities was primarily due to net outflow of cash used in operating activities of $20.2 million, the purchases of marketable debt securities of $4.9 million, capital expenditures of $1.0 million and an equity investment purchase of $1.0 million, partially offset by proceeds from the sale of marketable debt securities.
Cash and cash equivalents and marketable debt securities held in U.S. Dollars at:

| September 29, 2018 |  | December 30, 2017
Domestic locations | $ | 34,672,549 |  |  | $ | 55,488,190 |
International locations | 6,212,222 |  |  | 6,110,496 |
Subtotal cash and cash equivalents marketable debt securities held in U.S. dollars | 40,884,771 |  |  | 61,598,686 |
Cash and cash equivalents held in other currencies and converted to U.S. dollars | 5,318,245 |  |  | 7,156,998 |
Total cash and cash equivalents and marketable debt securities | $ | 46,203,016 |  |  | $ | 68,755,684 |

We have no plans to repatriate the cash and cash equivalents held in our foreign subsidiaries FDD and Kopin Software Ltd. and, as such, we have not recorded any deferred tax liability with respect to such cash. The manufacturing operations at our Korean facility, Kowon, have ceased. Kowon had approximately $11.0 million of cash and cash equivalents at September 29, 2018, which we anticipate will eventually be remitted to the U.S. and, accordingly, we have recorded deferred tax liabilities associated with its unremitted earnings.
As part of the NVIS acquisition, additional payments by the Company of up to $2.0 million may be required if certain future operating performance milestones are met and the selling stockholders remain employed with NVIS through March 2020. As there is a requirement to remain employed to earn the contingent payments, these contingent payments will be treated as compensation expense.
We expect to expend between $1.0 million and $1.5 million on capital expenditures in 2018.
We own approximately 93% of Kowon, our Korean subsidiary. The owners of the remaining 7% have expressed a desire to sell their shares to us. We are evaluating whether to purchase the shares.
The Company has entered into an agreement that is subject to certain closing conditions, including government approvals. Under the agreement the Company is to make a capital contribution of approximately $5.3 million (the Company's capital contribution under the agreement is 35.0 million RMB).
Historically, we have financed our operations primarily through public and private placements of our equity securities and cash generated from operations. We believe our available cash resources will support our operations and capital needs for at least the next twelve months.
There has been no seasonal pattern to our sales in fiscal years 2018 and 2017.

Item 3. | Quantitative and Qualitative Disclosures about Market Risk

We invest our excess cash in high-quality U.S. government, government-backed (i.e.: Fannie Mae, FDIC guaranteed bonds and certificates of deposit) and corporate debt instruments, which bear lower levels of relative risk. We believe that the effect, if any, of reasonably possible near-term changes in interest rates on our financial position, results of operations and cash flows should not be material to our cash flows or income. It is possible that interest rate movements would increase our unrealized gain or loss on debt securities. We are exposed to changes in foreign currency exchange rates primarily through our translation of our foreign subsidiaries' financial position, results of operations, and transaction gains and losses as a result of non-U.S. dollar denominated cash flows related to business activities in Asia and Europe, and remeasurement of U.S. dollars to the British pound and the Korean won, the functional currency of our U.K. and Korean subsidiaries, respectively. We are also exposed to the effects of exchange rates in the purchase of certain raw materials, which are in U.S. dollars, but the price on future purchases is subject to change based on the relationship of the Japanese yen to the U.S. dollar. We do not currently hedge
29

Table of Contents
our foreign currency exchange rate risk. We estimate that any market risk associated with our international operations or investments is unlikely to have a material adverse effect on our business, financial condition or results of operation. Our portfolio of marketable debt securities is subject to interest rate risk although our intent is to hold securities until maturity. The credit rating of our investments may be affected by the underlying financial health of the guarantors of our investments. We use silicon wafers but do not enter into forward or futures hedging contracts to mitigate against risks related to the price of silicon.

Item 4. | Controls and Procedures

Evaluation of Disclosure Controls and Procedures
As of September 29, 2018, the Company conducted an evaluation under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer (its principal executive officer and principal financial officer, respectively) regarding the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of September 29, 2018, defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The term “disclosure controls and procedures” means controls and other procedures that are designed to ensure that information required to be disclosed by the Company in reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the requisite time periods and that such disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports that we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were effective as of September 29, 2018.
Changes in Internal Control over Financial Reporting
There have been no changes in the Company’s internal control over financial reporting that occurred during the quarter ended September 29, 2018 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Part II. OTHER INFORMATION

Item 1. | Legal Proceedings

The Company may engage in legal proceedings arising in the ordinary course of business. Claims, suits, investigations and proceedings are inherently uncertain and it is not possible to predict the ultimate outcome of such matters and our business, financial condition, results of operations or cash flows could be affected in any particular period.
BlueRadios, Inc. v. Kopin Corporation, Civil Action No. 16-02052-JLK (D. Col.):
On August 12, 2016, BlueRadios, Inc. ("BlueRadios") filed a complaint in the U.S. District Court for the District of Colorado, alleging that the Company breached a contract between it and BlueRadios concerning a joint venture between the Company and BlueRadios to design, develop and commercialize micro-display products with embedded wireless technology referred to as “Golden-i” breached the covenant of good faith and fair dealing associated with that contract, breached its fiduciary duty to BlueRadios, and misappropriated trade secrets owned by BlueRadios in violation of Colorado law (C.R.S. § 7-74-104(4)) and the Defend Trade Secrets Act (18 U.S.C. § 1836(b)(1)). BlueRadios further alleges that the Company was unjustly enriched by its alleged misconduct, BlueRadios is entitled to an accounting to determine the amount of profits obtained by the Company as a result of its alleged misconduct, and the inventorship on at least ten patents or patent applications owned by the Company need to be corrected to list BlueRadios’ employees as inventors and thereby list BlueRadios as co-assignees of the patents. BlueRadios seeks monetary, declaratory, and injunctive relief.
On October 11, 2016, the Company filed its Answer and Affirmative Defenses. The parties are in the midst of discovery, with the close of all discovery currently set for March 14, 2019. A trial date has not yet been set by the Court. The Company has not concluded a loss from this matter is probable; therefore, we have not recorded an accrual for litigation or claims related to this matter for the period ended September 29, 2018. The Company will continue to evaluate information as it becomes known and will record an estimate for losses at the time or times when it is both probable that a loss has been incurred and the amount of the loss is reasonably estimable.
30

Table of Contents

Item 1A. | Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for our fiscal year ended December 30, 2017. The risks discussed in our Annual Report on Form 10-K, as modified by the following additional and revised risk factor, and the information in “Forward-Looking Statements” included in this Form 10-Q, could materially affect our business, financial condition and future results. The risks described in our Annual Report on Form 10-K and this Form 10-Q are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or operating results.
Changes in government trade policies could increase the cost of our products, which may materially adversely affect our sales or profitability. We depend on Chinese, Taiwanese, and Korean foundries for the manufacture of integrated circuits for our Display products. The U.S. government recently proposed, among other actions, imposing new or higher tariffs on specified imported products originating from China in response to what it characterizes as unfair trade practices, and China has responded by proposing new or higher tariffs on specified products imported from the U.S. In notices published on April 6, 2018 and June 20, 2018, the Office of the United States Trade Representative issued a determination and requests for public comment under Section 301 under the Trade Act of 1974 (the “Notices”) concerning the proposed imposition of an additional 25% tariff on specified products from China, which products comprised approximately $50.0 billion in estimated annual trade value for calendar year 2018. The list of products set forth in the Notices included diodes, integrated circuits and other products that we import from China as part of our supply chain. Further tariffs may be imposed in the future, including a tariff of 25% on integrated circuits, which may be imposed after the completion of a public comment period, which was expected to end on July 31, 2018. Tariffs on components that we import from China or other nations that have imposed, or may in the future impose, tariffs would cause our expenses to increase, which would adversely affect our profitability unless we were able to exclude our products from the tariffs or we raise prices for our products, which may result in our products becoming less attractive relative to products offered by our competitors. In addition, future actions or escalations by either the U.S. or China that affect trade relations may also affect our business, or that of our suppliers or customers, and we cannot provide any assurances as to whether such actions will occur or the form that they may take. Moreover, it is uncertain to what extent, if any, the U.S. tariffs on components that we import from China will affect the Taiwanese foundries on which we depend, in part because many Taiwanese foundries conduct parts of their manufacturing in China.
A protectionist trade environment in either the U.S. or those foreign countries in which we do business, such as a change in the current tariff structures, export compliance or other trade policies, may materially and adversely affect our ability to sell our products in foreign markets. To the extent that our sales or profitability are affected negatively by any such tariffs or other trade actions, our business and results of operations may be materially adversely affected.

Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds

We did not sell any securities during the three months ended September 29, 2018 that were not registered under the Securities Act.
31

Table of Contents
Item 6. Exhibits

Exhibit No. |  | Description
31.1 |  | Certification of John C.C. Fan, Chief Executive Officer, filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) *
31.2 |  | Certification of Richard A. Sneider, Chief Financial Officer, filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) *
32.1 |  | Certification of John C.C. Fan, Chief Executive Officer, furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) **
32.2 |  | Certification of Richard A. Sneider, Chief Financial Officer, furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) **
101.INS |  | XBRL Instance Document*
101.SCH |  | XBRL Taxonomy Extension Schema Document*
101.CAL |  | XBRL Taxonomy Calculation Linkbase Document*
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB |  | XBRL Taxonomy Label Linkbase Document*
101.PRE |  | XBRL Taxonomy Presentation Linkbase Document*

* | Submitted electronically herewith

** | Furnished and not filed herewith

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at September 29, 2018 (Unaudited) and December 30, 2017, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 29, 2018 and September 30, 2017, (iii) Condensed Consolidated Statement of Comprehensive (Loss) Income (Unaudited) for the three and nine months ended September 29, 2018 and September 30, 2017, (iv) Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) for the nine months ended September 29, 2018, (v) Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 29, 2018 and September 30, 2017, and (vi) Notes to Unaudited Condensed Consolidated Financial Statements.
32

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  | KOPIN CORPORATION (Registrant)
Date: | November 8, 2018 |  | By: | /S/ John C.C. Fan
|  |  |  | John C.C. Fan
|  |  |  | President, Chief Executive Officer and Chairman of the Board of Directors
|  |  |  | (Principal Executive Officer)
Date: | November 8, 2018 |  | By: | /S/ R ICHARD A. S NEIDER
|  |  |  | Richard A. Sneider
|  |  |  | Treasurer and Chief Financial Officer
|  |  |  | (Principal Financial and Accounting Officer)

33